Jazz Pharmaceuticals Acquires SpringWorks’ FAAH Inhibitor Program for Post-Traumatic Stress Disorder

 Jazz Pharmaceuticals Acquires SpringWorks’ FAAH Inhibitor Program for Post-Traumatic Stress Disorder

Jazz Pharmaceuticals Acquires SpringWorks’ FAAH Inhibitor Program for Post-Traumatic Stress Disorder

Shots:

  • SpringWorks to receive $35M as upfront and $ 375M as clinical, regulatory, and commercial milestones and is eligible to receive royalties on future net sales of PF-04457845. Jazz to get an exclusive license of all assets relating to the FAAH inhibitor program including PF-04457845
  • The acquisition magnifies Jazz’s neuroscience pipeline into a new disease area, further optimizes SpringWorks’ strategic focus on targeted oncology
  • Jazz will initially focus on developing PF-04457845 as a treatment in PTSD for patients with inadequate response to currently approved therapies

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Spring Works

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post